LCKLSL hydrochloride
Modify Date: 2024-01-05 00:26:16
LCKLSL hydrochloride structure
|
Common Name | LCKLSL hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 533902-29-3 | Molecular Weight | 675.88 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H57N7O8S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LCKLSL hydrochlorideLCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles[1]. |
| Name | LCKLSL |
|---|
| Description | LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles[1]. |
|---|---|
| Related Catalog | |
| Target |
Annexin A2 (AnxA2)[1] |
| In Vitro | In human retinal microvascular endothelial cells (RMVECs), treatment with LCKLSL (0-2 mg) inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions[1]. |
| In Vivo | Application of LCKLSL in two in vivo models (in chicken chorioallantoic membrane and murine Matrigel plug assays) of angiogenesis demonstrates suppression of the angiogenic responses. Treatment with the LCKLSL peptide significantly decreases the vascular length. At a dose of 5 μg/mL, the LCKLSL peptide significantly decreases the number of vascular branches, junctions and end-points[1]. |
| References |
| Molecular Formula | C30H57N7O8S |
|---|---|
| Molecular Weight | 675.88 |